Titanovo Logo
Back to Cell Types

MSTO-211HHomo sapiens (Human)Cancer cell line

Also known as: MeSoTheliOma-211H, 211H, MSTO-211, MSTO211H, MSTO-211 H

🤖 AI SummaryBased on 14 publications

Quick Overview

Malignant mesothelioma cell line with known genetic alterations.

Detailed Summary

MSTO-211H is a malignant pleural mesothelioma cell line established from a Japanese patient. It is characterized by specific genetic alterations, including mutations in the BAP1 gene and the NF2 gene. These alterations are associated with the Hippo signaling pathway, which plays a critical role in cell proliferation and tumor suppression. MSTO-211H has been used in studies to investigate the molecular mechanisms underlying mesothelioma progression and to evaluate potential therapeutic targets. The cell line is also noted for its utility in understanding the role of the Hippo pathway in cancer biology.

Research Applications

Investigation of genetic alterations in mesotheliomaStudy of the Hippo signaling pathwayEvaluation of therapeutic targets for mesotheliomaAnalysis of BAP1 and NF2 gene mutations

Key Characteristics

Mutations in BAP1 and NF2 genesInvolvement in the Hippo signaling pathwayUsed for studying mesothelioma progression
Generated on 6/17/2025

Basic Information

Database IDCVCL_1430
SpeciesHomo sapiens (Human)
Tissue SourcePleural effusion[UBERON:UBERON_0000175]

Donor Information

Age62
Age CategoryAdult
SexMale
Racecaucasian

Disease Information

DiseasePleural mesothelioma
LineagePleura
SubtypePleural Mesothelioma, Biphasic Type
OncoTree CodePLBMESO

DepMap Information

Source TypeATCC
Source IDACH-000335_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleLATS2p.Met785_Leu798del14 (c.2355_2396del42)Heterozygous-from parent cell line MSTO-211H
Gene fusionLATS1LATS1-PSEN1--from parent cell line MSTO-211H
Gene deletionCDKN2A-HomozygousPossiblePubMed=26870271

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X,Y
CSF1PO
11,12
D13S317
11,14
D16S539
13
D18S51
16,18
D19S433
13,14
D21S11
28,31
D2S1338
20,24
D3S1358
15
D5S818
12
D7S820
8,12
D8S1179
13
FGA
21
Penta D
11,12
Penta E
7,13
TH01
8,9.3
TPOX
11
vWA
16,18
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

DOIPubMedPMC

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

DOIPubMedPMC

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOIPubMedPMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOIPubMedPMC

Screening human cell lines for viral infections applying RNA-Seq data analysis.

Uphoff C.C., Pommerenke C., Denkmann S.A., Drexler H.G.

PLoS ONE 14:E0210404-E0210404(2019).

DOIPubMedPMC

E-cadherin expression is correlated with focal adhesion kinase inhibitor resistance in merlin-negative malignant mesothelioma cells.

Kato T., Sato T., Yokoi K., Sekido Y.

Oncogene 36:5522-5531(2017).

DOIPubMed

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOIPubMedPMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOIPubMedPMC

Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells.

Yokoi K., Sekido Y.

Cancer Sci. 106:990-999(2015).

DOIPubMedPMC

Hippo pathway gene mutations in malignant mesothelioma: revealed by RNA and targeted exon sequencing.

Asamura H., Gemma A., Yamada T.

J. Thorac. Oncol. 10:844-851(2015).

DOIPubMed

Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma.

Rice D.C., Tsao A., Wistuba I.I.

J. Thorac. Oncol. 9:998-1007(2014).

DOIPubMedPMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOIPubMedPMC

The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Powell S.N., Zhou Q., Shen R.-L., Olshen A.B., Rusch V.W., Ladanyi M.

Nat. Genet. 43:668-672(2011).

DOIPubMedPMC

LATS2 is a tumor suppressor gene of malignant mesothelioma.";

Sekido Y.

Cancer Res. 71:873-883(2011).

DOIPubMed

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

DOIPubMedPMC

Genomic profiling of malignant pleural mesothelioma with array-based comparative genomic hybridization shows frequent non-random chromosomal alteration regions including JUN amplification on 1p32.

Sekido Y.

Cancer Sci. 98:438-446(2007).

DOIPubMedPMC

Establishment and characterization of four malignant pleural mesothelioma cell lines from Japanese patients.

Yokoi K., Horio Y., Shimokata K., Sekido Y., Hida T.

Cancer Sci. 97:387-394(2006).

DOIPubMedPMC

Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling.

Sugarbaker D.J., Bueno R.

Am. J. Pathol. 166:1827-1840(2005).

DOIPubMedPMC

Characterization of the state of differentiation of six newly established human non-small-cell lung cancer cell lines.

Jaques G., Gropp C., Haeder M.

Differentiation 37:158-171(1988).

DOIPubMed